This is a working overview of vaccine adjuvant, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-31 and is reviewed periodically as new material appears.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Prolonged exposure to dry ice can cause severe skin damage through frostbite, and the fog produced may also hinder attempts to withdraw from contact in a safe manner. Because it sublimes into large quantities of carbon dioxide gas, which could pose a danger of hypercapnia, dry ice should only be exposed to open air in a well-ventilated environment. For this reason, in the context of laboratory safety dry ice is assigned label precaution P403: "Store in a well-ventilated place." Industrial dry ice may contain contaminants that make it unsafe for direct contact with food. Tiny dry ice pellets used in dry ice blast cleaning do not contain oily residues. Dry ice is assigned a UN number, a code for hazardous substances: UN 1845. Dry ice is not classified as a dangerous substance by the European Union, or as a hazardous material by the United States Department of Transportation for ground transportation. However, in the US, it is regulated as a dangerous good when shipped by air or water. International Air Transport Association (IATA) regulations require specific diamond-shaped black-and white labelling to be placed on the package. The package must have adequate ventilation so that it will not rupture from pressure in the event that the Dry Ice begins to sublime in the packaging. The Federal Aviation Administration in the US allows airline passengers to carry up to 2.5 kg (5.5 lb) per person either as checked baggage or carry-on baggage, when used to refrigerate perishables.
India Archived 11 January 2021 at the Wayback Machine. The World Factbook. Central Intelligence Agency. India web resources provided by GovPubs at the University of Colorado Boulder Libraries India from BBC News Wikimedia Atlas of India Geographic data related to India at OpenStreetMap Key Development Forecasts for India from International Futures
X.906|ISO/IEC 19793: Information technology - Open distributed processing - Use of UML for ODP system specifications". This document (usually referred to as UML4ODP) defines use of the Unified Modeling Language 2 (UML 2; ISO/IEC 19505), for expressing the specifications of open distributed systems in terms of the viewpoint specifications defined by the RM-ODP. It defines a set of UML Profiles, one for each viewpoint language and one to express the correspondences between viewpoints, and an approach for structuring them according to the RM-ODP principles. The purpose of "UML4ODP" to allow ODP modelers to use the UML notation for expressing their ODP specifications in a standard graphical way; to allow UML modelers to use the RM-ODP concepts and mechanisms to structure their large UML system specifications according to a mature and standard proposal; and to allow UML tools to be used to process viewpoint specifications, thus facilitating the software design process and the enterprise architecture specification of large software systems. In addition, ITU-T Rec. X.906 | ISO/IEC 19793 enables the seamless integration of the RM-ODP enterprise architecture framework with the Model-Driven Architecture (MDA) initiative from the OMG, and with the service-oriented architecture (SOA).
Sources: en.wikipedia.org
== Research == Metreleptin is being investigated for the treatment of diabetes and/or hypertriglyceridemia, in patients with rare forms of lipodystrophy, syndromes characterized by abnormalities in adipose tissue distribution, and severe metabolic abnormalities. The FDA approved Metreleptin injection for treating complications of leptin deficiency in February 2014. In a three-year study of metreleptin in patients with lipodystrophy organized by the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health, metreleptin treatment was associated with a significant decrease in blood glucose (A1c decreased from 9.4% at baseline to 7.0% at study end) and triglyceride concentration (from 500 mg/dl at baseline to 200 mg/dl at study end). Metreleptin is effective in most patients with generalized lipodystrophy where circulating leptin levels are extremely low. Analogous to insulin replacement for patients with type 1 diabetes, metreleptin restores the function of a deficient hormone. However, in patients with partial lipodystrophy where there is only a relative leptin deficiency, the response to metreleptin is not universal. This may or may not be due to anti-leptin antibodies. Metreleptin is undergoing research for its potential benefit in the treatment of anorexia nervosa. It is hypothesized that the gradual loss of body fat mass, and more specifically the ensuing low leptin levels, escalate the preexisting drive for thinness into an obsessive-compulsive-like and addictive-like state.
===== Dipterans ===== If flies are fed serotonin, they are more aggressive; flies depleted of serotonin still exhibit aggression, but they do so much less frequently. In their crops it plays a vital role in digestive motility produced by contraction. Serotonin that acts on the crop is exogenous to the crop itself and 2012 research suggested that it probably originated in the serotonin neural plexus in the thoracic-abdominal synganglion. In 2011 a Drosophila serotonergic mushroom body was found to work in concert with Amnesiac to form memories. In 2007 serotonin was found to promote aggression in Diptera, which was counteracted by neuropeptide F – a surprising find given that they both promote courtship, which is usually similar to aggression in most respects.
==== Antimicrobial photodynamic therapy ==== PDT may also be utilized to treat multidrug-resistant skin, wound, or other superficial infections. This is known as antimicrobial photodynamic therapy (aPDT) or photodynamic inactivation (PDI). aPDT has been observed to be effective against both gram-positive and gram-negative bacteria such as Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, and Mycobacterium. aPDT has shown lowered efficacy on some other bacterial species, such as Klebsiella pneumoniae and Acinetobacter baumannii. This is likely due to factors such as cell wall thickness and membrane potential. Many studies utilizing aPDT focus on the application of the photosensitizer through leakage from a hydrogel, which has been found to increase wound healing speed of skin infections through the upregulation of vascular endothelial growth factor (VEGF) and hypoxia inducible factor (HIF). This controlled leakage allows for prolonged but limited generation of ROS, lowering the impact on human cell viability due to ROS cytotoxicity. It is unlikely for drug resistance to photosensitizers to form due to the nontoxic nature of the photosensitizer itself as well as the ROS generation mechanism of action, which cannot be prevented outside of hypoxic environments. Certain dental infections (peri-implantitis, periodontitis) are more difficult to treat with PDT as opposed to photothermal therapy due to the requirement of oxygen, though a significant response is still observed.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
Reconstituted solutions are typically kept refrigerated at two to eight degrees Celsius when used within a short window, or frozen in aliquots for longer periods. Repeated freeze-thaw cycles are avoided because they can reduce recovery of intact peptide.